Your account is not claimed yet. You can sign up with ORCID to claim your account.

Andrea Chiricozzi (A Chiricozzi)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2014-2023
Publications (10 Years): 67

Top Venues

Journal of the European Academy of Dermatology and Venereology : JEADV

Expert opinion on biological therapy

Expert opinion on investigational drugs

The Journal of dermatological treatment

Catholic University of Rome - Fondazione Policlinico Universitario Agostino Gemelli IRCCS

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Catholic University of Rome - Fondazione Policlinico Universitario Agostino Gemelli IRCCS Mar 1o 2019

Italy

Researcher :: Institute of Dermatology

Publications

Andrea Chiricozzi, Michela Ortoncelli, Donatella Schena, Niccolò Gori, Silvia Mariel Ferrucci, Graziella Babino, Maddalena Napolitano, Maria Concetta Fargnoli, Luca Stingeni, Mariateresa Rossi, Marco Romanelli, Riccardo Balestri, Michele Pellegrino, Aurora Parodi, Alberto Maria Bertoldi, Giovanni Palazzo, Flaminia Antonelli, Annalisa Pitino, Giovanni Tripepi, Gabriella Fabbrocini, Anna Balato, Angelo Valerio Marzano, Giampiero Girolomoni, Simone Ribero, Ketty Peris
Correction to: Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation. American journal of clinical dermatology (2023)
Niccolò Gori, Elena Ippoliti, Flaminia Antonelli, Ketty Peris, Andrea Chiricozzi
Successful response of upadacitinib in the treatment of atopic dermatitis lesions involving sensitive and visible areas resistant to dupilumab. Clinical and experimental dermatology (2023)
Andrea Chiricozzi, Michela Ortoncelli, Donatella Schena, Niccolò Gori, Silvia Mariel Ferrucci, Graziella Babino, Maddalena Napolitano, Maria Concetta Fargnoli, Luca Stingeni, Mariateresa Rossi, Marco Romanelli, Riccardo Balestri, Michele Pellegrino, Aurora Parodi, Alberto Maria Bertoldi, Giovanni Palazzo, Flaminia Antonelli, Annalisa Pitino, Giovanni Tripepi, Gabriella Fabbrocini, Anna Balato, Angelo Valerio Marzano, Giampiero Girolomoni, Simone Ribero, Ketty Peris
Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation. American journal of clinical dermatology (2023)
Giulia Coscarella, Dalma Malvaso, Maria Mannino, Giacomo Caldarola, Barbara Fossati, Clara De Simone, Andrea Chiricozzi, Ketty Peris
The preclinical discovery and development of deucravacitinib for the treatment of psoriasis. Expert opinion on drug discovery (2023)
Giacomo Caldarola, Andrea Chiricozzi, Matteo Megna, P Dapavo, A Giunta, M Burlando, P Malagoli, V Dini, Marco Mariani, Gabriella Fabbrocini, P Quaglino, Luca Bianchi, A Parodi, Ketty Peris, C De Simone
Real-life experience with ixekizumab in plaque psoriasis: a multi-center, retrospective, 3-year study. Expert opinion on biological therapy (2023)
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, Rosa Giuseppa Angileri, Federico Bardazzi, Nicoletta Bernardini, Martina Burlando, Carlo G Carrera, Andrea Chiricozzi, Paolo Dapavo, Valentina Dini, Gabriella Fabbrocini, Francesca Maria Gaiani, Marco Galluzzo, Claudia Giofré, Claudio Guarneri, Francesco Loconsole, Giovanna Malara, Lorenzo Marcelli, Matteo Megna, Stefano Piaserico, Marina Talamonti, Antonio Costanzo, Alessandra Narcisi
Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104-week multicenter retrospective study - IL PSO (ITALIAN LANDSCAPE PSORIASIS). Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Marina Talamonti, Filomena Russo, Giovanna Malara, Katharina Hansel, Manuela Papini, Angelo Cattaneo, Aurora Parodi, Andrea Chiricozzi, Piergiorgio Malagoli, Federico Bardazzi, Valeria Brazzelli, Paolo Dapavo, Paolo Gisondi, Cristina Zane, Concetta Potenza, Franca Cantoresi, Maria-Concetta Fargnoli, Sara Trevisini, Pina Brianti, Leonardo Pescitelli, Giovanni Gigante, Marta Bartezaghi, Luisa Caputo, Elisabetta Aloisi, Antonio Costanzo, null null
Efficacy and Safety of Secukinumab in Elderly Patients with Moderate to Severe Plaque-Type Psoriasis: Post-Hoc Analysis of the SUPREME Study. Clinical, cosmetic and investigational dermatology 16 (2023)
Andrea Chiricozzi, Giampiero Girolomoni
Shedding Light on Novel Pathogenic and Therapeutic Aspects Related to Immune-Mediated Skin Diseases. Vaccines 11 (4) (2023)
Andrea Chiricozzi, Matteo Megna, Alessandro Giunta, Carlo Giovanni Carrera, Paolo Dapavo, Anna Balato, Piergiorgio Malagoli, Stella Mazzoccoli, Aurora Parodi, Silvia Sabatino, Carlotta Buzzoni, Chu-Han Huang, Alessandra Narcisi
Ixekizumab is effective in the long-term management in moderate-to-severe plaque psoriasis: results from an Italian retrospective cohort study (the LOTIXE study). The Journal of dermatological treatment 34 (1) (2023)
Federico Salfi, Giulia Amicucci, Michele Ferrara, Daniela Tempesta, Andrea De Berardinis, Andrea Chiricozzi, Ketty Peris, Maria-Concetta Fargnoli, Maria Esposito
The role of insomnia in the vulnerability to depressive and anxiety symptoms in atopic dermatitis adult patients. Archives of dermatological research (2023)
Luigi Gargiulo, Luciano Ibba, P Malagoli, R G Angileri, F Bardazzi, Nicoletta Bernardini, M Burlando, C G Carrera, Andrea Chiricozzi, P Dapavo, Valentina Dini, G Fabbrocini, F M Gaiani, Marco Galluzzo, C Giofré, C Guarneri, F Loconsole, G Malara, L Marcelli, Matteo Megna, Stefano Piaserico, Marina Talamonti, Antonio Costanzo, A Narcisi
Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: a 104-week multicenter retrospective study - IL PSO (ITALIAN LANDSCAPE PSORIASIS). Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, Rosa Giuseppa Angileri, Federico Bardazzi, Nicoletta Bernardini, Martina Burlando, Carlo G Carrera, Andrea Chiricozzi, Paolo Dapavo, Valentina Dini, Gabriella Fabbrocini, Francesca Maria Gaiani, Marco Galluzzo, Claudia Giofré, Claudio Guarneri, Francesco Loconsole, Giovanna Malara, Lorenzo Marcelli, Matteo Megna, Stefano Piaserico, Marina Talamonti, Antonio Costanzo, Alessandra Narcisi
Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104-week multicenter retrospective study - IL PSO (ITALIAN LANDSCAPE PSORIASIS). Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Flaminia Antonelli, Dalma Malvaso, Giacomo Caldarola, Clara De Simone, Ketty Peris, Andrea Chiricozzi
Infectious adverse events in patients with atopic dermatitis treated with baricitinib. Immunotherapy (2023)
Giacomo Caldarola, Andrea Chiricozzi, Matteo Megna, P Dapavo, A Giunta, M Burlando, P Malagoli, V Dini, Marco Mariani, Gabriella Fabbrocini, P Quaglino, Luca Bianchi, A Parodi, Ketty Peris, C De Simone
Real-life experience with ixekizumab in plaque psoriasis: a multi-center, retrospective, 3-year study. Expert opinion on biological therapy (2023)
Laura Calabrese, Dalma Malvaso, Flaminia Antonelli, Maria Mannino, Ketty Peris, Andrea Chiricozzi
Investigational systemic drugs for moderate to severe plaque psoriasis: What's new? Expert opinion on investigational drugs (2023)
Andrea Chiricozzi, Giampiero Girolomoni
Shedding Light on Novel Pathogenic and Therapeutic Aspects Related to Immune-Mediated Skin Diseases. Vaccines 11 (4) (2023)
Niccolò Gori, Elena Ippoliti, Ketty Peris, Andrea Chiricozzi
Head and neck atopic dermatitis: still a challenging manifestation in the biologic era. Expert opinion on biological therapy (2023)
Giacomo Caldarola, Gennaro Marco Falco, Laura Calabrese, Alessandra D'Amore, Andrea Chiricozzi, Marco Mariani, Gerardo Palmisano, Clara De Simone, Ketty Peris
Drug survival of biologics and non-biologics in patients affected by palmoplantar psoriasis: a "real-world", mono-center experience. International journal of dermatology (2023)
Andrea Chiricozzi, Lucia Di Nardo, N Gori, F Antonelli, L Pinto, G Cuffaro, G Piro, G Savino, G Tortora, K Peris
Dupilumab-associated ocular adverse events are predicted by low tear break-up time and correlate with high IL-33 tear concentrations in patients with atopic dermatitis. Experimental dermatology (2023)
Maria-Concetta Fargnoli, Federico Bardazzi, Luca Bianchi, Paolo Dapavo, Gabriella Fabbrocini, Paolo Gisondi, Giuseppe Micali, Anna Maria Offidani, Giovanni Pellacani, Nevena Skroza, Rosa Giuseppa Angileri, Martina Burlando, Campanati Anna, Carlo Giovanni Carrera, Andrea Chiricozzi, Andrea Conti, Clara De Simone, Vito Di Lernia, Enzo Errichetti, Marco Galluzzo, Claudio Guarneri, Claudia Lasagni, Serena Lembo, Francesco Loconsole, Matteo Megna, Maria Letizia Musumeci, Francesca Prignano, Antonio Giovanni Richetta, Emanuele Trovato, Marina Venturini, Ketty Peris, Piergiacomo Calzavara Pinton
Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement. Journal of clinical medicine 12 (10) (2023)
Andrea Chiricozzi, Giampiero Girolomoni
Shedding Light on Novel Pathogenic and Therapeutic Aspects Related to Immune-Mediated Skin Diseases. Vaccines 11 (4) (2023)
Giacomo Caldarola, Eleonora De Luca, Marco Mariani, Andrea Chiricozzi, Ketty Peris, Clara De Simone
Drug survival of methotrexate and predictor factors for discontinuation in psoriasis. International journal of dermatology (2023)
Andrea Chiricozzi, Martina Maurelli, Laura Calabrese, Ketty Peris, Giampiero Girolomoni
Overview of Atopic Dermatitis in Different Ethnic Groups. Journal of clinical medicine 12 (7) (2023)
Dalma Malvaso, Laura Calabrese, Andrea Chiricozzi, Flaminia Antonelli, Giulia Coscarella, Pietro Rubegni, Ketty Peris
IL-17 Inhibition: A Valid Therapeutic Strategy in the Management of Hidradenitis Suppurativa. Pharmaceutics 15 (10) (2023)
Laura Calabrese, Dalma Malvaso, Flaminia Antonelli, Maria Mannino, Ketty Peris, Andrea Chiricozzi
Investigational systemic drugs for moderate to severe plaque psoriasis: What's new? Expert opinion on investigational drugs (2023)
Cataldo Patruno, Gabriella Fabbrocini, Giuseppe Lauletta, Valeria Boccaletti, Cristiana Colonna, Riccardo Cavalli, Iria Neri, Michela Ortoncelli, Donatella Schena, Luca Stingeni, Katharina Hansel, Vincenzo Piccolo, Veronica Di Brizzi, Concetta Potenza, Ersilia Tolino, Luca Bianchi, Sara Manti, Rocco De Pasquale, Vito Di Lernia, Lucia Caminiti, Elena Galli, Paola Coppo, Andrea Chiricozzi, Clara De Simone, Cristina Guerriero, Fabrizio Giuseppe Amoruso, Eugenio Provenzano, Salvatore Leonardi, Amelia Licari, Gian Luigi Marseglia, Antonino Palermo, Sabrina Di Pillo, Daniele Russo, Viviana Moschese, Vincenzo Patella, Tiziana Peduto, Caterina Ferreli, Paola Zangari, Federica Veronese, Samantha Federica Berti, Michaela Gruber, Elena Pezzolo, Stefania Termine, Rosanna Satta, Federica Dragoni, Maria Esposito, Maria Concetta Fargnoli, Paolo Chiodini, Ylenia Vallone, Francesca di Vico, Vincenzo Picone, Maddalena Napolitano
A 52-week multicenter retrospective real-world study on effectiveness and safety of dupilumab in children with atopic dermatitis aged from 6 to 11 years. The Journal of dermatological treatment 34 (1) (2023)
Paolo Romita, Caterina Foti, Gianluca Calianno, Andrea Chiricozzi
Successful treatment with secukinumab in an HIV-positive psoriatic patient after failure of apremilast. Dermatologic therapy 35 (8) (2022)
Niccolò Gori, Simone Cappilli, Alessandro Di Stefani, Francesco Tassone, Andrea Chiricozzi, Ketty Peris
Assessment of alopecia areata universalis successfully treated with upadacitinib. International journal of dermatology (2022)
Andrea Chiricozzi, Francesco Bellinato, Paolo Romita, Paolo Gisondi
Psoriasis: talking points from recent clinical trials. Expert opinion on investigational drugs 31 (12) (2022)
Federica Ricceri, Andrea Chiricozzi, Ketty Peris, Francesca Prignano
Successful use of anti-IL-23 molecules in overweight-to-obese psoriatic patients: A multicentric retrospective study. Dermatologic therapy 35 (11) (2022)
Andrea Chiricozzi, Francesco Bellinato, Paolo Romita, Paolo Gisondi
Psoriasis: talking points from recent clinical trials. Expert opinion on investigational drugs (2022)
Niccolò Gori, Andrea Chiricozzi, Franco Marsili, Silvia Mariel Ferrucci, Paolo Amerio, Vincenzo Battarra, Salvatore Campitiello, Antonio Castelli, Maurizio Congedo, Monica Corazza, Antonio Cristaudo, Gabriella Fabbrocini, Giampiero Girolomoni, Giovanna Malara, Giuseppe Micali, Giovanni Palazzo, Aurora Parodi, Annalisa Patrizi, Giovanni Pellacani, Paolo Pigatto, Eugenio Provenzano, Pietro Quaglino, Marco Romanelli, Mariateresa Rossi, Paola Savoia, Ketty Peris
National Information Campaign Revealed Disease Characteristic and Burden in Adult Patients Suffering from Atopic Dermatitis. Journal of clinical medicine 11 (17) (2022)
Andrea Chiricozzi, Niccolò Gori, Alessandra Narcisi, Anna Balato, Alessio Gambardella, Michela Ortoncelli, Angelo Valerio Marzano, Riccardo Balestri, Giovanni Palazzo, Michele Pellegrino, Marco Romanelli, Giovanni Tripepi, Ketty Peris, Antonio Costanzo, null null
Effectiveness and Safety of Upadacitinib in the Treatment of Moderate-Severe Atopic Dermatitis: A Multicentric, Prospective, Real-World, Cohort Study. Drugs in R&D 22 (3) (2022)
E De Luca, N Gori, Andrea Chiricozzi, A Di Stefani, Ketty Peris
Periocular molluscum contagiosum in an atopic dermatitis patient treated with upadacitinib. The Journal of dermatological treatment 33 (7) (2022)
Andrea Chiricozzi, Francesco Bellinato, Paolo Romita, Paolo Gisondi
Psoriasis: Talking points from recent clinical trials. Expert opinion on investigational drugs (2022)
Laura Calabrese, Andrea Chiricozzi, Clara De Simone, Barbara Fossati, Alessandra D'Amore, Ketty Peris
Pharmacodynamics of Janus kinase inhibitors for the treatment of atopic dermatitis. Expert opinion on drug metabolism & toxicology 18 (5) (2022)
Andrea Chiricozzi, Francesco Bellinato, Paolo Romita, Paolo Gisondi
Psoriasis: talking points from recent clinical trials. Expert opinion on investigational drugs 31 (12) (2022)
Francesco Tassone, Simone Cappilli, Flaminia Antonelli, Ruggiero Zingarelli, Andrea Chiricozzi, Ketty Peris
Alopecia Areata Occurring after COVID-19 Vaccination: A Single-Center, Cross-Sectional Study. Vaccines 10 (9) (2022)
Andrea Chiricozzi, Niccolò Gori, Martina Maurelli, Paolo Gisondi, Giacomo Caldarola, Clara De Simone, Ketty Peris, Giampiero Girolomoni
Biological agents targeting interleukin-13 for atopic dermatitis. Expert opinion on biological therapy 22 (5) (2022)
Francesco Bellinato, Andrea Chiricozzi, Stefano Piaserico, Giovanni Targher, Paolo Gisondi
Could Targeted Pharmacotherapies Exert a "Disease Modification Effect" in Patients with Chronic Plaque Psoriasis? International journal of molecular sciences 23 (21) (2022)
Luca Stingeni, Leonardo Bianchi, Elettra Antonelli, Elena Sofia Caroppo, Silvia Mariel Ferrucci, Carlotta Gurioli, Michela Ortoncelli, Gabriella Fabbrocini, Eustachio Nettis, Donatella Schena, Maddalena Napolitano, Massimo Gola, Laura Bonzano, MariaTeresa Rossi, Anna Belloni Fortina, Anna Balato, Ketty Peris, Caterina Foti, Fabrizio Guarneri, Marco Romanelli, Cataldo Patruno, Paola Savoia, Maria Esposito, Filomena Russo, Enzo Errichetti, Tommaso Bianchelli, Luca Bianchi, Giovanni Pellacani, Claudio Feliciani, Annamaria Offidani, Monica Corazza, Giuseppe Micali, Nicola Milanesi, Giovanna Malara, Andrea Chiricozzi, Marta Tramontana, Katharina Hansel, null null
A 52-week update of a multicentre Italian real-world experience on effectiveness and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis. Journal of the European Academy of Dermatology and Venereology : JEADV (2022)
Jonathan Ian Silverberg, David N Adam, Matthew Zirwas, Sunil Kalia, Jan Gutermuth, Andreas Pinter, Andrew E Pink, Andrea Chiricozzi, Sébastien Barbarot, Thomas Mark, Ann-Marie Tindberg, Stephan Weidinger
Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis. American journal of clinical dermatology 23 (4) (2022)
Marco Galluzzo, Marina Talamonti, Nicoletta Bernardini, Andrea Chiricozzi, Clara De Simone, Claudio Bonifati, Pierluigi Bruni, Federico Diotallevi, Maria Esposito, Dario Graceffa, Katharina Hansel, Francesco Loconsole, Gaia Moretta, Cristina Mugheddu, Manuela Papini, Antonio Giovanni Richetta, Nevena Skroza, Laura Atzori, Maria-Concetta Fargnoli, Severino Persechino, Annamaria Offidani, Luca Stingeni, Ketty Peris, Concetta Potenza, Luca Bianchi
Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year. Expert opinion on biological therapy (2022)
Marina Talamonti, Marco Galluzzo, Andrea Chiricozzi, Pietro Quaglino, Gabriella Fabbrocini, Paolo Gisondi, Angelo Valerio Marzano, Concetta Potenza, Andrea Conti, Aurora Parodi, Stefano Piaserico, Federico Bardazzi, Giuseppe Argenziano, Franco Rongioletti, Luca Stingeni, Giuseppe Micali, Francesco Loconsole, Maria Teresa Rossi, Maria Rita Bongiorno, Claudio Feliciani, Pietro Rubegni, Paolo Amerio, Maria Concetta Fargnoli, Paolo Pigatto, Paola Savoia, Steven Paul Nisticò, Sandra Giustini, Andrea Carugno, Serafinella Patrizia Cannavo', Giulia Rech, Francesca Prignano, Annamaria Offidani, Maurizio Lombardo, Iris Zalaudek, Luca Bianchi, Ketty Peris
Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study. Expert opinion on biological therapy 21 (2) (2021)
Katharina Hansel, A Zangrilli, L Bianchi, Ketty Peris, Andrea Chiricozzi, A Offidani, Federico Diotallevi, Maria-Concetta Fargnoli, Maria Esposito, P Amerio, Giulio Gualdi, L Bianchi, Luca Stingeni
A 52-week update of a multicentre real-life experience on effectiveness and safety of risankizumab in psoriasis. Journal of the European Academy of Dermatology and Venereology : JEADV (2021)
Andrea Chiricozzi, Marina Talamonti, Clara De Simone, Marco Galluzzo, Niccolò Gori, Gabriella Fabbrocini, Angelo Valerio Marzano, Giampiero Girolomoni, Annamaria Offidani, Maria Teresa Rossi, Luca Bianchi, Antonio Cristaudo, Maria Teresa Fierro, Luca Stingeni, Giovanni Pellacani, Giuseppe Argenziano, Annalisa Patrizi, Paolo Pigatto, Marco Romanelli, Paola Savoia, Pietro Rubegni, Caterina Foti, Nicola Milanesi, Anna Belloni Fortina, Maria Rita Bongiorno, Teresa Grieco, Sergio Di Nuzzo, Maria Concetta Fargnoli, Andrea Carugno, Alberico Motolese, Franco Rongioletti, Paolo Amerio, Riccardo Balestri, Concetta Potenza, Giuseppe Micali, Cataldo Patruno, Iris Zalaudek, Maurizio Lombardo, Claudio Feliciani, Lucia Di Nardo, Fabrizio Guarneri, Ketty Peris, null null
Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: Data from the DA-COVID-19 registry. Allergy 76 (6) (2021)
Marco Galluzzo, Andrea Chiricozzi, Elisa Cinotti, Giovanna Brunasso, Maurizio Congedo, Maria Esposito, Chiara Franchi, Giovanna Malara, Alessandra Narcisi, Stefano Piaserico, Rossana Tiberio, Giuseppe Argenziano, Gabriella Fabbrocini, Aurora Parodi
Tildrakizumab for treatment of moderate to severe psoriasis: an expert opinion of efficacy, safety, and use in special populations. Expert opinion on biological therapy (2021)
A V Marzano, Andrea Chiricozzi, G Giovanardi, G Argenziano, Vincenzo Bettoli, L Bianchi, P Dapavo, V Dini, G Fabbrocini, G Micali, A M Offidani, C Potenza, F Prignano, G Gualberti, V Saragaglia, Franco Rongioletti
Creation of a severity index for hidradenitis suppurativa that includes a validated quality-of-life measure: the HIDRAscore. Journal of the European Academy of Dermatology and Venereology : JEADV 34 (8) (2020)
Andrea Chiricozzi, Giuseppe Micali, S Veraldi
The patient journey: a voyage from diagnosis to hidradenitis suppurativa multidisciplinary unit. Journal of the European Academy of Dermatology and Venereology : JEADV (2020)
Simone Garcovich, F S Bersani, Andrea Chiricozzi, C De Simone
Mass quarantine measures in the time of COVID-19 pandemic: psychosocial implications for chronic skin conditions and a call for qualitative studies. Journal of the European Academy of Dermatology and Venereology : JEADV 34 (7) (2020)
Paolo Gisondi, Francesco Bellinato, Andrea Conti, P Dapavo, S Piaserico, C De Simone, Andrea Chiricozzi, Annunziata Dattola, P Malagoli, G Malara, A Campanati, M Burlando, Maria Esposito, L Gallo, Giampiero Girolomoni
Consensus on the place in therapy of TNF-α inhibitors in the treatment of patients with chronic plaque psoriasis. Journal of the European Academy of Dermatology and Venereology : JEADV 34 (9) (2020)
Laura Calabrese, Dalma Malvaso, Andrea Chiricozzi, Sara Tambone, Dario Francesco D'Urso, Cristina Guerriero, Ketty Peris
Baricitinib: therapeutic potential for moderate to severe atopic dermatitis. Expert opinion on investigational drugs 29 (10) (2020)
Andrea Chiricozzi, Martina Maurelli, Ketty Peris, Giampiero Girolomoni
Targeting IL-4 for the Treatment of Atopic Dermatitis. ImmunoTargets and therapy 9 (2020)
Katharina Hansel, A Zangrilli, L Bianchi, Ketty Peris, Andrea Chiricozzi, A Offidani, Federico Diotallevi, Maria-Concetta Fargnoli, Maria Esposito, P Amerio, Giulio Gualdi, L Bianchi, Luca Stingeni
A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16-week real-life experience during the COVID-19 pandemic. Journal of the European Academy of Dermatology and Venereology : JEADV 35 (3) (2020)
Andrea Chiricozzi, Paolo Gisondi, Francesco Bellinato, Giampiero Girolomoni
Immune Response to Vaccination in Patients with Psoriasis Treated with Systemic Therapies. Vaccines 8 (4) (2020)
Federico Pirro, Giacomo Caldarola, Andrea Chiricozzi, Sara Tambone, Marco Mariani, Laura Calabrese, Dario Francesco D'Urso, Clara De Simone, Ketty Peris
The impact of COVID-19 pandemic in a cohort of Italian psoriatic patients treated with biological therapies. The Journal of dermatological treatment (2020)
Andrea Chiricozzi, Paolo Gisondi, Giampiero Girolomoni
The pharmacological management of patients with comorbid psoriasis and obesity. Expert opinion on pharmacotherapy 20 (7) (2019)
Andrea Conti, F Peccerillo, P Amerio, Anna Balato, F Bardazzi, L Bianchi, M Burlando, S P Cannavò, Andrea Chiricozzi, P Dapavo, C De Simone, M C Fargnoli, A Gambardella, Paolo Gisondi, P Malagoli, G Malara, C Mugheddu, A M Offidani, S Piaserico, Francesca Prignano, L Stingeni, G Pellacani
Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: results from a multicentre experience. The British journal of dermatology 180 (6) (2019)
Andrea Chiricozzi, Anna Balato, Curdin Conrad, Andrea Conti, Paolo Dapavo, Paulo Ferreira, Francesca Maria Gaiani, Luiz Leite, Piergiorgio Malagoli, Pedro Mendes-Bastos, Matteo Megna, Francesco Messina, Alessia Nidegger, Giulia Odorici, Salvatore Panduri, Stefano Piaserico, Leonardo Piscitelli, Francesca Prignano, Simone Ribero, Joana Valerio, Tiago Torres
Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study. The Journal of dermatological treatment 31 (5) (2019)
Andrea Chiricozzi, Diego Peroni, Giampiero Girolomoni
Testing biologics and intracellular signaling inhibitors on pediatric atopic dermatitis: a stairway to modern therapeutic approaches. Expert opinion on investigational drugs 27 (9) (2018)
Andrea Chiricozzi, Luca Antonioli, Salvatore Panduri, Matteo Fornai, Marco Romanelli, Corrado Blandizzi
Risankizumab for the treatment of moderate to severe psoriasis. Expert opinion on biological therapy 19 (1) (2018)
Paolo Gisondi, L Bianchi, Piergiacomo Calzavara-Pinton, A Conti, Andrea Chiricozzi, M Fimiani, M Pellegrino, A Giunta, Francesca Prignano, R Tiberio, Marina Venturini, G Girolomoni
Etanercept biosimilar SB4 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry. The British journal of dermatology 180 (2) (2018)
Annalisa Tonini, Bruno Gualtieri, Salvatore Panduri, Marco Romanelli, Andrea Chiricozzi
A new class of biologic agents facing the therapeutic paradigm in psoriasis: anti-IL-23 agents. Expert opinion on biological therapy 18 (2) (2017)
Andrea Chiricozzi, Nicola Pimpinelli, Federica Ricceri, Giovanni Bagnoni, Laura Bartoli, Mauro Bellini, Luca Brandini, Marzia Caproni, Antonio Castelli, Michele Fimiani, Franco Marsili, Carlo Mazzatenta, Maria Chiara Niccoli, Salvatore Panduri, Michele Pellegrino, Riccardo Sirna, Walter Volpi, Marco Romanelli, Francesca Prignano
Treatment of psoriasis with topical agents: Recommendations from a Tuscany Consensus. Dermatologic therapy 30 (6) (2017)
Pietro Salvo, Valentina Dini, Arno Kirchhain, Agata Janowska, Teresa Oranges, Andrea Chiricozzi, Tommaso Lomonaco, Fabio Di Francesco, Marco Romanelli
Sensors and Biosensors for C-Reactive Protein, Temperature and pH, and Their Applications for Monitoring Wound Healing: A Review. Sensors (Basel, Switzerland) 17 (12) (2017)
Steven Paul Nistico, Andrea Chiricozzi, Federica Tamburi, Giovanni Cannarozzo
Lasers and Energy Devices for the Skin: Conventional and Unconventional Use. BioMed research international 2016 (2016)
Andrea Chiricozzi, Salvatore Panduri, Valentina Dini, Annalisa Tonini, Bruno Gualtieri, Marco Romanelli
Optimizing acitretin use in patients with plaque psoriasis. Dermatologic therapy 30 (2) (2016)
Andrea Saggini, Sergio Chimenti, Andrea Chiricozzi
IL-6 as a druggable target in psoriasis: focus on pustular variants. Journal of immunology research 2014 (2014)

Andrea Chiricozzi.css-eqlu8i{font-size:small;padding-left:4px;} (A Chiricozzi)

Publication Activity (10 Years)

Top Topics

Top Venues

Andrea Chiricozzi (A Chiricozzi)